TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic

Contributed by: PR Newswire

Tags

Thioredoxin-SEK

More Like This

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

PR Newswire associated0

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

Debiopharm to Showcase Research Results of Their First-in-class Anti-staphylococcal Program at IDWeek 2024 in Los Angeles

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition